Neurocrine Biosciences disclosed precise financial terms and integration milestones for its $575 million acquisition of Soleno Therapeutics, centering on VYKAT XR (diazoxide choline) for Prader-Willi syndrome. The company provided updated revenue projections and regulatory timelines that position the deal as platform extension rather than therapeutic pivot.
Neurocrine structured the transaction as $325 million upfront cash with $250 million in contingent payments tied to regulatory and commercial milestones through 2027. VYKAT XR entered the portfolio with FDA approval already secured in March 2024 and commercial launch underway. Neurocrine guided to $50-70 million in VYKAT XR revenue for 2025, reflecting four full quarters of integrated sales force effort. The company specified that peak revenue potential sits north of $500 million annually, assuming label expansion into pediatric hyperphagia indications currently in Phase III development.
The acquisition matters because Neurocrine operates a commercial infrastructure built for chronic CNS conditions—tardive dyskinesia, Parkinson's, endometriosis—with field teams already calling on neurology and psychiatry practices that overlap substantially with Prader-Willi treatment centers. VYKAT XR slots into existing relationships rather than requiring new channel development. Soleno's orphan drug brought 1,200 patients on therapy at acquisition close, a base Neurocrine expects to double within eighteen months by leveraging its payor contracting muscle and nurse educator network. The company disclosed it will fold VYKAT XR into the same specialty pharmacy hub model that supports INGREZZA, its $1.9 billion tardive dyskinesia franchise, eliminating redundant patient support infrastructure.
The deal also loads optionality into Neurocrine's mid-stage pipeline without requiring internal R&D build-out in rare metabolic disease. Soleno's pediatric trial for hyperphagia in hypothalamic obesity reads out in Q3 2026, with potential for $150-200 million in additional peak revenue if data support label expansion. Neurocrine management specified on the acquisition call that it will not increase its R&D budget to support the VYKAT program—existing clinical operations capacity absorbs the workload. That discipline matters to allocators because it signals the company views this as commercial tuck-in, not a costly therapeutic bet requiring fresh capital deployment.
Operators and allocators should track three near-term events. First, Neurocrine reports Q1 2025 earnings in late April, which will include the first full quarter of integrated VYKAT XR sales and revised full-year revenue guidance that incorporates Soleno's contribution. Second, the pediatric hypothalamic obesity trial hits its enrollment target in Q2 2025, setting up the Q3 2026 readout that determines whether the $250 million milestone payments trigger. Third, watch for any shifts in Neurocrine's capital allocation stance—management has historically returned excess cash via buybacks, but this acquisition consumed $325 million in balance sheet liquidity, reducing near-term repurchase capacity.
Neurocrine ended Q4 2024 with $1.1 billion in cash and investments, down from $1.5 billion pre-acquisition, leaving roughly $800 million in dry powder after accounting for working capital needs.